Home › InDex Pharmaceuticals AB Regains European Rights To Kappaproct In Ulcerative Colitis
 

Keywords :   


InDex Pharmaceuticals AB Regains European Rights To Kappaproct In Ulcerative Colitis

2015-06-30 21:13:39| Appliances - Topix.net

June 30, 2015 - InDex Pharmaceuticals today announced the termination of a license agreement with Almirall S.A. relating to the drug candidate KappaproctA for the treatment of ulcerative colitis. Under the agreement, which was signed in March 2014, Almirall licensed exclusive rights to KappaproctA for the European market.

Tags: rights index european pharmaceuticals

Category:Consumer Goods and Services

Latest from this category

All news
04.11Swisscom TV connections down 12,000 in 3Q 2024
04.11Comcast domestic video subscribers down 365,000 in 3Q 2024
04.1115 jeans 'more durable' than 150 pair in tests
04.11The environmental campaigners fighting against data centres
04.11Sainsbury's to rival Aldi prices in smallest stores
04.11Lying talent agent took our money and dreams
03.11Reeves 'not immune' to criticism over NI hike
03.11Unite union may bring legal action over winter fuel payments
Consumer Goods and Services »
04.11Tropical Depression Eighteen Graphics
04.11Tropical Depression Eighteen Public Advisory Number 4A
04.11Remnants of Patty Graphics
04.11Atlantic Tropical Weather Outlook
04.11Eastern North Pacific Tropical Weather Outlook
04.11Paper Excellence Group Rebrands as Domtar
04.11Registration Open for 2025 Waterborne Symposium
04.11ROSS Ribbon Blenders Provide Safe, Efficient Bulk Blending
More »